Purpose

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: - Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD - Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Condition

Eligibility

Eligible Ages
Between 18 Years and 85 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Signed informed consent - History of ASCVD

Exclusion Criteria

  • Participants known to be currently receiving investigational drug in a clinical study - Participants with a diagnosis of end-stage renal disease or requiring dialysis - Participants who have received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Other
Participants with history of ASCVD
Participants with history of ASCVD with known or unknown Lp(a) values.
  • Other: Lp(a) Screening
    Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.

More Details

Status
Completed
Sponsor
Amgen

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.